Zimmermann Martine 4
4 · LIGAND PHARMACEUTICALS INC · Filed Jun 9, 2026
Research Summary
AI-generated summary of this filing
Ligand (LGND) Director Martine Zimmermann Receives RSU Award
What Happened
Martine Zimmermann, a director of Ligand Pharmaceuticals (LGND), received equity awards on June 5, 2026: two grants of restricted stock units (RSUs) totaling 3,774 RSUs (836 + 2,938) at $0 acquisition price. To cover the tax liability on the RSU settlement, 182 shares were withheld by the company at $237.00 per share, a withholding value of $43,134. The RSU grants were approved by the Board at the company's annual meeting.
Key Details
- Transaction date: June 5, 2026 (Form filed June 9, 2026). Filing appears timely (within the standard two business days).
- Grants: 836 RSUs and 2,938 RSUs granted (total 3,774 RSUs) — acquisition price $0 (non-cash awards).
- Tax withholding: 182 shares withheld at $237.00/share = $43,134 (disposition for tax payment).
- Vesting: RSUs fully vest on the earlier of the next annual meeting of stockholders or the first anniversary of the grant (per footnotes).
- Shares owned after the transaction: not disclosed in the provided filing excerpt.
- Transaction codes: A = Award/Grant, F = Tax withholding in connection with RSU settlement.
Context
These were board-approved RSU grants (non-cash awards) rather than open-market purchases or option exercises. The tax-withholding action (shares withheld) is a common administrative step when RSUs settle and does not necessarily indicate buying or selling intent.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-05+836→ 5,279 total - Tax Payment
Common Stock
[F2]2026-06-05$237.00/sh−182$43,134→ 5,097 total - Award
Non-Qualified Stock Option (right to buy)
[F3]2026-06-05+2,938→ 2,938 totalExercise: $237.00Exp: 2036-06-05→ Common Stock (2,938 underlying)
Footnotes (3)
- [F1]Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
- [F2]Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.
- [F3]Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.